SCHEMBL23988351

SCHEMBL23988351

Cc1cnc(CC(O)c2nc3cc(OC(F)F)ccc3[nH]2)c(C)c1OCC(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SARM1 Q6SZW1 1/20 0.45
ATP4A P20648 7/20 0.44
ATP4B P51164 7/20 0.44
ATP1A1 P05023 6/20 0.44
ATP1B1 P05026 6/20 0.44
ATP1A3 P13637 6/20 0.44
ATP1B2 P14415 6/20 0.44
ATP1A2 P50993 6/20 0.44
ATP1B3 P54709 6/20 0.44
FXYD2 P54710 6/20 0.44
ATP1A4 Q13733 6/20 0.44
PRCP P42785 2/20 0.35
BRS3 P32247 2/20 0.34
KMT2A Q03164 6/20 0.33
MEN1 O00255 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 2/20 0.33
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988500 0.92 SARM1 (0.45) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988580 0.91 SARM1 (0.46) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988589 0.89 ATP4A (0.55) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988401 0.85 CYP3A4 (0.45) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988407 0.84 SARM1 (0.61) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL24571950 0.84 KMT2A (0.41) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988370 0.83 SARM1 (0.47) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988271 0.83 ATP4A (0.44) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988270 0.83 SARM1 (0.45) SARM1ATP4AATP4BATP1A1ATP1B1
SCHEMBL23988577 0.80 BRS3 (0.52) SARM1ATP4AATP4BATP1A1ATP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202796-A1 CXCL10 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-06-30 US disclosed
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202796-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 SARM1 3076/4885ATP4A 4581/4885ATP4B 4629/4885
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 SARM1 3076/4885ATP4A 4581/4885ATP4B 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.